Gill Gauravpal S, Vlacancich Raymond, Mehta Neil, Chaturvedi Mansi, Papolos Alexander
Internal Medicine, MedStar Washington Hospital Center, Washington, DC, USA.
Cardiology, MedStar Washington Hospital Center, Washington, DC, USA.
Cureus. 2020 Jun 15;12(6):e8638. doi: 10.7759/cureus.8638.
Cardiac involvement in coronavirus disease 2019 (COVID-19) commonly accompanies multi-organ system failure with acute respiratory syndrome; however, infrequently myocarditis and pericardial effusions may be isolated, yet fulminant. In this report, we highlight significant variations in cardiac involvement and presentation among patients with COVID-19. This article reports two cases of fulminant myocarditis in COVID-19 positive patients who presented to our facility with contrasting symptoms, laboratory and imaging findings. A 65-year-old patient A had a more typical presentation including respiratory distress, chest pain, ST-segment elevations on electrocardiogram (EKG), lymphopenia, elevated levels of inflammatory markers and cardiac troponin I. A 34-year-old patient B presented with shortness of breath and chest pain similar to patient A; however, she had isolated cardiac involvement with systolic dysfunction and an acute pericardial effusion causing tamponade physiology. Inflammatory marker and cardiac troponin I levels for patient B were within normal range. Patient A had a rapid progression of multi-organ system failure leading to her death within 24 hours from presentation on maximal inopressor support. Patient B, however, is one of few reported cases of cardiac tamponade and veno-arterial extracorporeal membrane oxygenation (VA-ECMO) use in COVID-19 who underwent pericardiocentesis and was additionally managed with colchicine and steroids, leading to complete recovery in systolic function within three weeks from initial presentation. Isolated myocardial dysfunction and pericardial effusions in COVID-19 may have catastrophic sequalae even in the absence of elevated biomarkers described in literature. Therefore, early detection and management of cardiac involvement is warranted. Additionally, the role of mechanical circulatory support devices and VA-ECMO in COVID-19 needs further investigation.
2019冠状病毒病(COVID-19)中的心脏受累通常伴随多器官系统衰竭及急性呼吸综合征;然而,心肌炎和心包积液也可能罕见地单独出现且病情凶险。在本报告中,我们强调了COVID-19患者心脏受累情况及表现的显著差异。本文报告了两例COVID-19阳性患者发生的暴发性心肌炎,这两名患者到我们机构就诊时症状、实验室检查及影像学表现截然不同。65岁的患者A表现更为典型,包括呼吸窘迫、胸痛、心电图(EKG)ST段抬高、淋巴细胞减少、炎症标志物及心肌肌钙蛋白I水平升高。34岁的患者B表现出与患者A相似的呼吸急促和胸痛;然而,她仅有心脏受累,存在收缩功能障碍及急性心包积液导致心包填塞。患者B的炎症标志物及心肌肌钙蛋白I水平在正常范围内。患者A多器官系统衰竭进展迅速,在接受最大剂量血管活性药物支持治疗后24小时内死亡。然而,患者B是少数报告的COVID-19合并心包填塞及使用静脉-动脉体外膜肺氧合(VA-ECMO)的病例之一,她接受了心包穿刺术,并加用秋水仙碱和类固醇治疗,在初次就诊后三周内心脏收缩功能完全恢复。即使在没有文献中所述生物标志物升高的情况下,COVID-19中的孤立性心肌功能障碍和心包积液也可能产生灾难性后果。因此,有必要对心脏受累进行早期检测和管理。此外,机械循环支持装置和VA-ECMO在COVID-19中的作用需要进一步研究。